Compass Therapeutics, Inc.
CMPX
$1.75
$0.052.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.51% | -23.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.42% | -23.00% | |||
| Operating Income | -35.42% | 18.65% | |||
| Income Before Tax | -43.43% | 19.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -43.43% | 19.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.43% | 19.85% | |||
| EBIT | -35.42% | 18.65% | |||
| EBITDA | -35.86% | 18.78% | |||
| EPS Basic | -44.36% | 19.79% | |||
| Normalized Basic EPS | -44.54% | 19.87% | |||
| EPS Diluted | -44.36% | 19.79% | |||
| Normalized Diluted EPS | -44.54% | 19.87% | |||
| Average Basic Shares Outstanding | -0.70% | 0.00% | |||
| Average Diluted Shares Outstanding | -0.70% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||